Thanks for posting this, Catherine. Is it my imagination, or does this trial seem to be less restrictive? The issues that stand in my way w/Merck & BMS are measurable disease, measurable disease on prior-irradiated skin, prior Remicade use (don’t remember if that one is BMS or Merck). This is SO frustrating!
Phase I Study of Anti-PD-1 Human Monoclonal Antibody MDX-1106 (BMS-936558) and Vaccine Therapy Comprising gp100:209-217(210M) Peptide, MART-1:26-35(27L) Peptide, gp100:280-288(288V) Peptide, NY-ESO-1 Peptide, and Montanide ISA 51 VG in Patients With Resected Stage IV Melanoma
There is NO concurrent use of steroids like Remicade…• At least 2 weeks since prior immunosuppressive doses of systemic medications, such as steroids or absorbed topical steroids (doses > 10 mg/day prednisone or equivalent)
Anti PD 1 helps keep the bodys immune system in overdrive and would defeat the purpose. I know I had some rashy hive like thing on my hands for two months, probably unrelated to the trial, and the derm doc rx’ed steroids, but my oncologist ( Dr Weber) found out before I started to take it and said no way…the rash eventually healed without the use of it.